Most Read Articles
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Iron infusion better than iron pill for treating anaemia after GI bleeding

20 Jul 2019

Administering ferric carboxymaltose (FCM) infusion results in faster and more efficient normalization of haemoglobin (Hb) and iron status parameters, with a better tolerability profile, when compared with oral ferrous sulphate (FeSulf) in patients with anaemia secondary to acute gastrointestinal (GI) bleeding, as shown in a recent study.

The 42-day study randomized 61 adult patients with Hb <10 g/dL upon discharge (day 0) to receive FCM (n=29; 1,000 mg on day 0; 500 or 1,000 mg on day 7; per label) or FeSulf (n=32; 325 mg/12 hours for 6 weeks).

Complete response rate (Hb ≥12 g/dL in women and ≥13 g/dL in men) at day 42, the primary outcome measure, was higher in the FCM than in the FeSulf group (100 percent vs 61.3 percent; p<0.001). Of note, this difference was observed as early as day 21 (85.7 percent vs 45.2 percent; p=0.001).

Results for secondary outcomes were also more favourable with FCM. Significantly more FCM- vs FeSulf-treated patients achieved partial response (Hb increment ≥2 g/dL from baseline) at days 21 (100 percent vs 67.7 percent; p=0.001) and 42 (100 percent vs 74.2 percent; p=0.003), as well as normalization of transferrin saturation to 25 percent by the end of the study period (76.9 vs 24.1 percent; p<0.001).

None of the patients in the FCM group reported any adverse event in comparison with 10 patients in the FeSulf group (eg, constipation and abdominal pain).

According to researchers, the present data could provide clinical support for the inclusion of ferric carboxymaltose into treatment schemes and guidelines in the management of patients with anaemia following acute haemorrhage of GI origin.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, Yesterday
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.